High Dose IFN-β Activates GAF to Enhance Expression of ISGF3 Target Genes in MLE12 Epithelial Cells

Interferon β (IFN- β ) signaling activates the transcription factor complex ISGF3 to induce gene expression programs critical for antiviral defense and host immune responses. It has also been observed that IFN- β activates a second transcription factor complex, γ-activated factor (GAF), but the sign...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 651254
Main Authors Kishimoto, Kensei, Wilder, Catera L., Buchanan, Justin, Nguyen, Minh, Okeke, Chidera, Hoffmann, Alexander, Cheng, Quen J.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.04.2021
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2021.651254

Cover

More Information
Summary:Interferon β (IFN- β ) signaling activates the transcription factor complex ISGF3 to induce gene expression programs critical for antiviral defense and host immune responses. It has also been observed that IFN- β activates a second transcription factor complex, γ-activated factor (GAF), but the significance of this coordinated activation is unclear. We report that in murine lung epithelial cells (MLE12) high doses of IFN- β indeed activate both ISGF3 and GAF, which bind to distinct genomic locations defined by their respective DNA sequence motifs. In contrast, low doses of IFN- β preferentially activate ISGF3 but not GAF. Surprisingly, in MLE12 cells GAF binding does not induce nearby gene expression even when strongly bound to the promoter. Yet expression of interferon stimulated genes is enhanced when GAF and ISGF3 are both active compared to ISGF3 alone. We propose that GAF may function as a dose-sensitive amplifier of ISG expression to enhance antiviral immunity and establish pro-inflammatory states.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Reviewed by: Cristina Lopez-Rodriguez, Pompeu Fabra University, Spain; Achille Broggi, Boston Children’s Hospital and Harvard Medical School, United States
Edited by: Liwu Li, Virginia Tech, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.651254